DOC

Program in Experimental Therapeutics

By Matthew Wright,2014-05-06 15:53
14 views 0
Program in Experimental Therapeutics

    Program in Experimental Therapeutics

    Eighth Annual Program Retreat

    Friday, June 22, 2007

    Paca-Pratt Building

    University of Maryland Greenebaum Cancer Center

    Program in Experimental Therapeutics

    Retreat 2007

    Friday, June 22, 2007

    Place: Paca-Pratt Building Conference Room 7B, Lower Level (below lobby)

    A G E N D A

Time Activity

    7:45-8:30 Registration, Continental Breakfast

    8:30-8:40 Cancer Center Director’s comments: Dr. Cullen

    8:40-9:00 Program Overview, Dr. Ross

    9:00-10:15 Scientific Session 1: Pharmacological Cancer Targets. Chair: Burger

     Tan, Wang (J-Y), Nakanishi, Gordon, Aurelian

10:15-10:30 BREAK

10:30-12:00 Scientific Session 2: Pharmacological and Immunological Chair: Garofalo

     Cancer Targets.

    Fenselau, Reitz, Wang (H), Hassel, Rapoport, Wolf

12:00-12:45 LUNCH

12:45-1:30 Keynote Address: “Retinoids, Stem Cells, and Cancer

    Lorraine Gudas, PhD, Professor and Chair, Department of Pharmacology, Weill

    Medical College of Cornell University

1:30-2:00 Scientific Session 3: Drug Design and Delivery. Chair: Ghandehari

     Ghandehari, Gerratana

2:00-2:15 BREAK

2:15-2:45 ET Pilot Grant Awards, 2006 update Chair: Ross

     Burger, Hosmane (Edelman)

2:45-4:45 Scientific Session 4: Clinical Trials Chair: Edelman

     Edelman, Sausville, Burger, Garofalo, Baer, Gojo, Badros, Temoshok

    Thanks to the Program Committee!

    Angelika Burger, Martin Edelman, Michael Garofalo, Hamid Ghandehari, Douglas Ross

    NOTE: All presentations are limited to 15 minutes

    (suggest 10 minutes for presentation, 5 minutes for Q&A)

    Program in Experimental Therapeutics

    Eighth Annual Program Retreat

    Friday, June 22, 2007

    Table of Contents

    AKPEK, Gorgun ................................................................................................................... 2 AURELIAN, Laure ................................................................................................................ 7 BADROS, Ashrof .................................................................................................................. 10 BAER, Maria ........................................................................................................................ 12 BASILE, John ....................................................................................................................... 15 BAUER, Ken ........................................................................................................................ 17 BURGER, Angelika .............................................................................................................. 19 CAREY, Gregory .................................................................................................................. 22 COOP, Andrew ..................................................................................................................... 25 CULLEN, Kevin .................................................................................................................... 27 DAVIDSON, Wendy .............................................................................................................. 29 DeTOLLA, Louis J. DeTolla .................................................................................................... 32 EDELMAN, Martin ................................................................................................................ 34 FANG, Hongbin .................................................................................................................... 37 FASANO, Alessio ................................................................................................................. 39 FELDMAN, Ricardo .............................................................................................................. 41 FENSELAU, Catherine ......................................................................................................... 44 GERRATANA, Barbara ......................................................................................................... 46 GHANDEHARI, Hamid ......................................................................................................... 48 GOJO, Ivana ........................................................................................................................ 51 GORDON, Sharon .................................................................................................................. 54 HASSEL, Bret....................................................................................................................... 56 HESS, John .......................................................................................................................... 60 HOSMANE, Ramachandra ................................................................................................... 62

    JIANG, Feng ........................................................................................................................ 65 KANNO, Mettassebia............................................................................................................ 67 KHANNA, Niharika ................................................................................................................. 70 MACKERELL, Alexander Jr .................................................................................................. 74 MEISENBERG, Barry ............................................................................................................. 76 MULLINS, C. Daniel ............................................................................................................. 78 NAKANISHI, Takeo .............................................................................................................. 80 NANDI, Asit .......................................................................................................................... 83 PENG, Hong ........................................................................................................................ 85 RAPOPORT, Aaron .............................................................................................................. 88 REITZ, Marvin ...................................................................................................................... 91 ROSS, Douglas .................................................................................................................... 94 SAUSVILLE, Edward ............................................................................................................ 98 STASS, Sanford ................................................................................................................... 105 SUNTHARALINGHAM, Mohan ............................................................................................ 107

    TAYLOR, Gregory ............................................................................................................... 109 TEMOSHOK, Lydia ............................................................................................................. 111 VARGHESE, Alexander ....................................................................................................... 118 WANG, Hongbin .................................................................................................................. 120 WANG, Lai-Xi ...................................................................................................................... 122 WOLF, Jeffrey ..................................................................................................................... 125 YAROWSKY, Paul ............................................................................................................... 127 ZIMRIN, Ann ....................................................................................................................... 129

     1

    Program in Experimental Therapeutics

    Eighth Annual Program Retreat

    Friday, June 22, 2007

    ABSTRACT FORM

Member Profile:

    Name: Gorgun Akpek, M.D., M.H.S.

    Academic Rank: Assistant Professor of Medicine

    Department: Medicine/Cancer Center

    School: University of Maryland School of Medicine

    Please list the major cancer-related SCIENTIFIC accomplishments of your entire career:

     Discovered that the extent of skin involvement is an independent prognostic

    indicator for chronic GVHD-specific survival

     Developed and validated a new prognostic model in chronic GVHD

     Described hepatitic-variant of graft-versus-host disease after donor lymphocyte

    infusion

     Described the patterns of gastrointestinal involvement in chronic GVHD

     Uncovered the curative role of allogeneic stem cell transplantation in Hodgkin‘s

    lymphoma

     Described the immune reconstitution after autologous stem cell transplant

    recipients in patients with AL-Amyloidosis

Please indicate which ET program goal(s) is/are met by your research:

     __ Goal 1: Identify targets for anticancer therapy

     __ Goal 2: Design rational targeted therapies

     _x_ Goal 3: Clinical trials

MOST IMPORTANT PLEASE COMPLETE THE FOLLOWING SECTION CAREFULLY,

    AND FOLLOW THE EXAMPLES BELOW.

Clinical Scientist: Dr. Gorgun Akpek, MD, MHS

    Dr. Akpek was recruited to our program as an expert in stem cell transplantation and graft-versus-host disease (GVHD) and as such has brought unique and previously unavailable expertise to our BMT program at Greenebaum Cancer Center. Indeed, Dr. Akpek has quickly established allogeneic SCT/GVHD clinic where he sees his patients with acute and chronic GVHD and conduct clinical trials. He is an essential contributor to the development of novel preventive approaches and treatments of GVHD. Dr. Akpek has been entrusted with developing an integrated program of laboratory and clinical investigation in the field of GVHD.

    Dr. Akpek is currently responsible for supporting the continued development and expansion of the autologous and allogeneic stem cell transplantation program at the Cancer Center. As one of the active members of allogeneic stem cell transplant team, he has been instrumental in developing institutional guidelines and research protocols for

     2

    reducing the incidence and severity of graft-versus-host disease (GVHD). He has been working with the multi- disciplinary faculty in developing innovative clinical trials.

    Dr. Akpek‘s research focuses primarily on novel treatments of acute and chronic GVHD. He already has many original journal articles in the most prestigious, peer-reviewed oncology and hematology journals. His research papers have been cited over seven hundred times by the other scientists working in the medical field. He has also given numerous presentations at national and international meetings.

    Dr. Akpek is one of the few investigators interested in prognosis of patients with chronic GVHD. During his tenure at Johns Hopkins University, he has studied various clinical and laboratory parameters to predict the mortality in a large number of patients with chronic GVHD. He has identified three important prognostic factors and developed a model predicting survival outcome at the time of initial diagnosis of chronic GVHD. His findings were published in Blood journal in 2001 and 2003.

    His proposed new clinical grading system in chronic GVHD was validated in a multi-center study to which he chaired between 2001 and 2003. This multi-center prospective database study, the first of its kind to be performed on this scale in the world, provided important information and introduced a new classification in chronic GVHD. Based upon his work in chronic GVHD, NIH Consensus forum has been created to better understand the pathogenesis, clinical and laboratory aspects of this debilitating condition. Six subcommittees that include world-known experts from United States and Europe were gathered for the NIH Chronic GVHD Consensus Project led by Dr. Steve Pavletic from NIH. Dr. Akpek has been serving in one of the subcommittees (Response Criteria) in the NIH Consensus Project in Chronic GVHD. See

    http://ccr.ncifcrf.gov/resources/gvhd/default.asp for further information.

    Since joining our faculty, Dr. Akpek has been a major contributor to the success of our clinical research projects. His success in this program is due in large part to his unique dual expertise as an extraordinary transplant physician and clinical researcher. Given his combined expertise in hematologic malignancies, stem cell transplantation and GVHD, he is playing a leading role in a number of important research studies in our transplant program. Among these, he is running a multi-center randomized placebo-controlled clinical trial to investigate potential therapeutic application of keratinocyte growth factor (KGF) in reducing the incidence and severity of mucositis and GVHD in allogeneic stem cell recipients. He is also serving as a PI in a large multicenter clinical trial investigating the role of mesenchymal stem cells in the treatment of steroid refractory acute GVHD. Dr. Akpek is the principle investigator of a CALGB Phase II clinical trial in the treatment of steroid refractory chronic GVHD by using Pentostatin. He is also leading a Phase I trial of MEDI-507 (anti-CD2 monocolonal antibody) in our institution in collaborating with NCI investigators in treating patients with T-cell malignancies.

    His other research priorities include the management of post-transplant relapse, utilization of novel imunomodulatory agents to induce tolerance while maintaining graft-versus-leukemia (GVL) effect. Based on his pilot data that is currently in press, he designed a dose-finding study to determine the safety and efficacy of sequential donor lymphocyte infusions in patients with posttransplant refractory infections. Working together with the other members of the BMT program, Dr. Akpek is currently working on new transplant modalities for patients who are not candidate for standard transplant protocols.

     3

    Currently, Dr. Akpek is working with two clinical research nurses. Other faculty members in the BMT program as stated below actively collaborate with Dr. Akpek in his GVHD trials. The current personnel engaged in the program have dedicated to improve the quantity and quality of patient care utilizing blood and marrow transplantation and certainly Dr. Akpek‘s work is filling the gap to improve the management of patients with GVHD. Dr.

    Akpek has financial and logistic support from our Cancer center as well as from various industrial companies for his studies. His ultimate goal is to conduct large scale clinical trials supported by National Institutes of Health.

Abstract:

    GRAFT-VERSUS-HOST DISEASE (GVHD)

    Transplantation of allogeneic hematopoietic stem cells harvested from bone marrow or

    peripheral blood of a donor (BMT) is currently the only curative treatment modality for

    many hematologic disorders and malignancies, which are otherwise fatal. Based on

    International Bone Marrow Transplantation (IBMTR) registry data, current estimates of

    annual numbers of allogeneic BMT are 12,000 to 15,000 worldwide, with continuing

    growth rate of 10 to 20% per year. Transplant-related mortality at 1 year after HLA-

    identical sibling transplants is about 30% and HLA-identical unrelated donor

    transplants is about 50%.

    A major cause of mortality after a successful transplant is the graft-versus-host

    disease (GVHD) mediated by immunologically competent T cells in the grafted marrow

    or blood. Skin, gut, liver, eyes, mouth are the most common sites where these donor

    T-cells attack and cause damage in the host (transplant recipient), which might lead to

    death if the damage is severe enough. Therefore, GVHD is a major barrier for the

    success of BMT. Clinically significant GVHD occurs in approximately half of the

    patients undergoing allogeneic blood or marrow transplantation, either of which is very

    costly (average $200,000 per patient) treatment modality. Approximately half of the

    patients who develop this complication succumb to death despite various

    immunosuppressive therapies. If a patient survives after acute form of GVHD (see

    picture 1), most of them (60%) subsequently develop chronic form of GVHD, which is

    the most devastating condition seen after allogeneic transplantation (see picture 2).

    Investigators recently reported the high rate of chronic GVHD after allogeneic

    peripheral blood stem cell transplantation, an expanding area of research and clinical

    application. Chronic GVHD is also associated with decreased quality of life, impaired

    functional performance status, and continued need for immunosuppressive

    medications. Although social and emotional functioning and satisfaction with

    transplantation are relatively preserved, chronic GVHD may cause abnormalities of

    growth and development in children, decrease general health status, sexual inactivity,

    and loss of employment in long-term survivors. Investigators have focused on

    developing better management strategies and treatment alternatives for this deadly, if

    not debilitating sequel of transplantation. For these reasons, both acute and chronic one of the major obstacles still facing the field of blood andmarrowGVHD is

    transplantation.

     4

    Please list one or two of your best cancer-related scientific PUBLICATIONS of your ENTIRE CAREER:

Akpek G*. Zahurak ML, Piantadosi S, Margolis, J, Dohorty J, Davidson R, Vogelsang Akpek G*. Zahurak ML, Piantadosi S, Margolis, J, Dohorty J, Davidson R, Vogelsang

    GB#. Development of a prognostic model for grading chronic GVHD. Blood 2001;97:1219-GB#. Development of a prognostic model for grading chronic GVHD. Blood 2001;97:1219-

    1226. 1226.

Akpek G*, Ambinder RF, Piantadosi S, Abrams RA, Brodsky RA, Vogelsang GB, Zahurak Akpek G*, Ambinder RF, Piantadosi S, Abrams RA, Brodsky RA, Vogelsang GB, Zahurak

    ML, Fuller D, Miller CB, Noga SJ, Fuchs E, Flinn IW, O'Donnell P, Seifter EJ, Mann RB, ML, Fuller D, Miller CB, Noga SJ, Fuchs E, Flinn IW, O'Donnell P, Seifter EJ, Mann RB,

    Jones RJ#. Long-Term Results of Blood and Marrow Transplantation for Hodgkin's Jones RJ#. Long-Term Results of Blood and Marrow Transplantation for Hodgkin's

    Lymphoma. J Clin Oncol 2001 Dec 1;19:4314-21 Lymphoma. J Clin Oncol 2001 Dec 1;19:4314-21

Akpek G*, Boitnott JK, Lee LA, Hallick JP, Torbenson M, Jacobsohn DA, Arai S, Anders Akpek G*, Boitnott JK, Lee LA, Hallick JP, Torbenson M, Jacobsohn DA, Arai S, Anders

    V, Vogelsang GB#. Hepatitic variant of graft-versus-host disease after donor lymphocyte V, Vogelsang GB#. Hepatitic variant of graft-versus-host disease after donor lymphocyte

    infusion. Blood 2002 Dec 1;100(12):3903-7 infusion. Blood 2002 Dec 1;100(12):3903-7

Akpek G*, Lee SJ, Flowers ME, Pavletic Z, Arora M, Lee S, Piantadosi S, Guthrie K, Akpek G*, Lee SJ, Flowers ME, Pavletic Z, Arora M, Lee S, Piantadosi S, Guthrie K,

    Lynch J, Horowitz MM, Antin JH, Weisdorf D, Martin P, Vogelsang GB#. Performance of a Lynch J, Horowitz MM, Antin JH, Weisdorf D, Martin P, Vogelsang GB#. Performance of a

    new clinical grading in chronic graft-versus-host disease: a multicenter study. Blood. 2003 new clinical grading in chronic graft-versus-host disease: a multicenter study. Blood. 2003

    Aug 1;102(3):802-9. Aug 1;102(3):802-9.

    Please list one or two of your best and MOST RECENT cancer-related scientific PUBLICATIONS:

Pavletic SZ*, Martin P, Lee SJ, Mitchell S, Jacobsohn D, Cowen EW, Turner ML, Akpek Pavletic SZ*, Martin P, Lee SJ, Mitchell S, Jacobsohn D, Cowen EW, Turner ML, Akpek

    G, Gilman A, McDonald G, Schubert M, Berger A, Bross P, Chien JW, Couriel D, Dunn JP, G, Gilman A, McDonald G, Schubert M, Berger A, Bross P, Chien JW, Couriel D, Dunn JP,

    Fall-Dickson J, Farrell A, Flowers ME, Greinix H, Hirshfiled S, Gerber L, Kim S, Knobler R, Fall-Dickson J, Farrell A, Flowers ME, Greinix H, Hirshfiled S, Gerber L, Kim S, Knobler R,

    Lachenbruch PA, Miller FW, Mitteleman B, Papadopoulos E, Parsons SK, Przepiorka D, Lachenbruch PA, Miller FW, Mitteleman B, Papadopoulos E, Parsons SK, Przepiorka D,

    Robinson M, Ward M, Reeve B, Rider LG, Schulman H, Schultz KR, Weisdorf D, Robinson M, Ward M, Reeve B, Rider LG, Schulman H, Schultz KR, Weisdorf D,

    Vogelsanf GB#. Measuring Therapeutic Response in Chronic Graft-versus-Host Disease: Vogelsanf GB#. Measuring Therapeutic Response in Chronic Graft-versus-Host Disease:

    National Institutes of Health Consensus Development Project on Criteria for Clinical Trials National Institutes of Health Consensus Development Project on Criteria for Clinical Trials

    in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group Report. Biol in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group Report. Biol

    Blood Marrow Transplant. 2006 Mar;12(3):252-66. Blood Marrow Transplant. 2006 Mar;12(3):252-66.

Akpek G. Titrating Graft-Versus-Host Disease: Is It Worth a Try? Bone Marrow Akpek G. Titrating Graft-Versus-Host Disease: Is It Worth a Try? Bone Marrow

    Transplantation 2006 Nov;38(10):653-6. Transplantation 2006 Nov;38(10):653-6.

Ilyas C, Forrest GN, Akpek G. Potential clinical benefit of using donor lymphocyte infusion Ilyas C, Forrest GN, Akpek G. Potential clinical benefit of using donor lymphocyte infusion

    in the treatment of refractory invasive fungal pneumonia. Bone Marrow Transplantation (in in the treatment of refractory invasive fungal pneumonia. Bone Marrow Transplantation (in

    press). press).

    Please write a paragraph describing your training, and past scientific accomplishments:

    I came to the University of Maryland from the Division of Hematologic Malignancies, Department of Oncology, at Johns Hopkins University School of Medicine. I earned my medical degree and completed my internship, residency and medical oncology fellowships at Hacettepe University School of Medicine in Ankara, Turkey, then completed a clinical fellowship program in Hematology and Oncology at Boston University Medical Center and

     5

    Bone Marrow Transplant fellowship at Johns Hopkins University School of Medicine. I subsequently joined the faculty at Johns Hopkins as a research associate.

    My clinical and research interest includes Hematologic Malignancies, Stem Cell Transplantation, Graft-Versus-Host Disease (GVHD), and Graft engineering. My most recent honors and awards include Henry Christian Award from the American Federation of Medical Research (AFMR), Travel Merit Award, American Society of Blood and Marrow Transplantation (ASBMT), Chief‘s Oncology Scholar Award (Boston University). I am recognized for my work on graft-versus-host disease (GVHD), a potentially life-threatening complication of allogeneic stem cell transplantation. I have published many articles and a book chapter on stem cell transplantation and GVHD. I have been invited to give lectures in international meetings in Japan and Turkey. I have chaired the oral th annual meeting in 2003. I have presentations sessions on chronic GVHD at ASH 44

    recently served as a scientific consultant in study section (NIH-K23).

Collaborators within the Cancer Center (list):

    Ivana Gojo, M.D., Aaron Rapoport, M.D., Saul Yanovich, M.D., Ashraf Badros, M.D., Douglas Ross, M.D., Gregg Hadley, M.D., Dean Mann, M.D.

Cancer Center Shared Services utilized or planned utilization:

     Translational research lab __Yes _x_No __Planned

     Biostatistics _x_Yes __No __Planned

     Biopolymer lab __Yes _x_No __Planned

     Clinical Research Mgmt. Ofc. _x_Yes __No __Planned

     Proteomics __Yes _x_No __Planned

     Tissue bank __Yes __No _x_Planned

     Flow cytometry __Yes __No _x_Planned

     6

    Program in Experimental Therapeutics

    Eighth Annual Program Retreat

    Friday, June 22, 2007

    ABSTRACT FORM

Member Profile:

    Name: Laure Aurelian

    Academic Rank: Professor

    Department: Pharmacology

    School: Medicine

    Please list the major cancer-related SCIENTIFIC accomplishments of your entire career:

     Elucidated mechanism of neoplastic transformation by viral oncogene

     Developed antisense technology to inhibit gene expression

     Cloned the first pro-apoptotic human heat shock protein (H11)

     Described the use of H11-targeted epigenetic approach to treat melanoma

Please indicate which ET program goal(s) is/are met by your research:

     _X_ Goal 1: Identify targets for anticancer therapy

     _X_ Goal 2: Design rational targeted therapies

     __ Goal 3: Clinical trials

    Please list one or two of your best cancer-related scientific PUBLICATIONS of your ENTIRE CAREER:

    Please list one or two of your best and MOST RECENT cancer-related scientific PUBLICATIONS:

    Smith, C. C., Nelson, J., Gober, M., Aurelian, L., Goswami, B. B. Binding of the GTP activating protein RAS-GAP by the PK domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10 PK) and activation of the RAS/MEK/MAPK mitogenic pathway are required for timely onset of HSV-2 growth. J. Virol. 74:10417-10429, 2000

    Smith, C.C., Yu, Y. X., Kulka, M., Aurelian, L. A novel human gene similar to the PK coding domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) codes for a serine threonine PK and is expressed in melanoma cells. J. Biol. Chem. 275:25690-25699, 2000

    Li, B., Smith, C.C., Laing, J.M., Gober, M.D., Liu, L., and Aurelian L. Forced expression of the heat shock protein H11 triggers growth arrest and apoptosis of melanoma cells through activation of Transforming growth factor activated kinase 1 (TAK1). Oncogene.

    2006 Dec 18 Epub ahead of print

     7

Please write a paragraph describing your training, and past scientific

    accomplishments:

    Laure Aurelian, Ph.D., is Professor of Pharmacology and Experimental Therapeutics and Director of the Virology/Immunology Laboratories at the University of Maryland, School of Medicine in Baltimore Maryland. Dr. Aurelian received a PhD in Microbiology from the Johns Hopkins University in 1966, and holds the distinction of being the first woman to obtain this degree from Johns Hopkins. In 1967, she joined the faculty of the Department of Microbiology at the Johns Hopkins School of Medicine, where she rose through the ranks reaching the professorial position. She moved to the University of Maryland School of Medicine in 1983. Dr. Aurelian is the co-founder of AuRx, a biotechnology company located in Maryland that is dedicated to the development of a therapeutic vaccine for herpes simplex virus. Dr. Aurelian is a pioneer in the development of antisense oligonucleotides for gene therapy and the developer of a therapeutic vaccine for herpes simplex virus that prevents recurrent disease. She cloned the only heat shock protein with pro-apoptotic activity, and is the discoverer of a viral gene with neuroprotective activity in neurons of the central nervous system. For this discovery and the development of a novel delivery vector for this gene, she won the 2001 Advisor Award from the National Collegiate of Inventors. She has trained over 50 pre-doctoral and postdoctoral fellows. Recent training awards are the Mentor Winner of the National Academic Medicine Fellowships, from the Bristol-Myers Squibb Fellowship in Academic Medicine and was the 2004 Distinguished Mentor Award from the Japanese Society of Investigative Dermatology. She served on various Study Sections for the National Institutes of Health. Among her various research awards, are the Distinguished Young Scientist Award from the Maryland Academy of Sciences, the DA Boyes Award from the Society of Gynecologic Oncology of British Columbia, an Honorary Membership in the K. Vehphvadze Scientific thSociety of Oncologists of the Georgian Republic, USSR, and the 900 Anniversary Medal

    of Distinction from the University of Bologna, Italy. She is cited in several biographical references including, Who is Who in America and Who’s Who in the World. She has been

    an invited and keynote speaker at many national and international scientific meetings. She has contributed over 260 articles to professional journals and texts and is the author of numerous book chapters and review articles. She serves on the editorial board of several journals, including Clinical and Diagnostic Laboratory Immunology, International Journal of

    Oncology, Frontiers in Bioscience, Genetic Vaccines and Therapy and Cancer Therapy.

    Please write a paragraph describing your current scientific work and goals pertinent to cancer research. Please mention in narrative form your collaborators, particularly those in the Cancer Center and ET program:

    Dr. Aurelian‘s research interests are in gene regulation and therapy. Focus is on the modulation of signaling pathways and apoptotic cascades, emphasizing the areas of carcinogenesis, gene therapy, neurotoxicity and cell injury. Apoptotic pathways triggered by the novel heat shock protein cloned in her laboratory, H11 are of major interest. Epigenetic targeting of H11 alone and in combination with other chemotherapeutic modalities for the treatment of cutaneous melanoma is a major area of present research interest and is supported by NIH funding.

Collaborators within the Cancer Center (list):

    Joseph W. Burnett, MD

     8

Report this document

For any questions or suggestions please email
cust-service@docsford.com